Successful Treatment of Animal Models of Rheumatoid Arthritis with Small-Molecule Cyclin-Dependent Kinase Inhibitors

Abstract

Intraarticular gene transfer of cyclin-dependent kinase (CDK) inhibitors to suppress synovial cell cycling has shown efficacy in treating animal models of rheumatoid arthritis. Endogenous CDK inhibitors also modulate immune function via a CDK-independent pathway. Accordingly, systemic administration of small molecules that inhibit CDK may or may not ameliorate arthritis. To address this issue, alvocidib (flavopiridol), known to be tolerated clinically for treating cancers, and a newly synthesized CDK4/6-selective inhibitor were tested for antiarthritic effects. In vitro, they inhibited proliferation of human and mouse synovial fibroblasts without inducing apoptosis. In vivo, treatment of collagen-induced arthritis mice with alvocidib suppressed synovial hyperplasia and joint destruction, whereas serum concentrations of anti-collagen type II (CII) Abs and proliferative responses to CII were maintained. Treatment was effective even when therapeutically administered. Treated mice developed arthritis after termination of treatment. Thus, immune responses to CII were unimpaired. The same treatment ameliorated arthritis induced by K/BxN serum transfer to lymphocyte-deficient mice. Similarly, the CDK4/6-selective inhibitor suppressed collagen-induced arthritis. Both small-molecule CDK inhibitors were effective in treating animal models of rheumatoid arthritis not by suppressing lymphocyte function. Thus, the two small-molecule CDK inhibitors ameliorated arthritis models in a distinctive way, compared with other immunosuppressive drugs.

A novel mTOR inhibitor is efficacious in a murine model of colitis

“…In our search for anticancer therapeutics, we have found that P2281 inhibits mTOR activity in colon cancer cells and suppresses DSS-induced colitis. Given that prior studies have demonstrated that compounds with anticancer activity show promising anti-inflammatory efficacy (39,43,51,59), the findings from this study, thus, reinforce the cross-therapeutic functionality of potential drugs.…”

Novel Role of Pin1 Induction in Type II Collagen-Mediated Rheumatoid Arthritis

“…Before sacrificing, arthritis in each limb of CII-treated mice was clinically assessed by visual edema scoring from 0 to 3, as follows: 0, no swelling; 1, detectable swelling in one joint; 2, nonsevere swelling in two or more joints; 3, severe swelling in two or more joints (19). The left hind limbs, including paws and ankles, were dissected, fixed immediately for 12 h in 10% neutralizing formaldehyde, decalcified in Calci-Clear Rapid (National Diagnostics) for 12 h, and embedded in paraffin.…”

p16INK4a Exerts an Anti-Inflammatory Effect through Accelerated IRAK1 Degradation in Macrophages

“…Comparable therapeutic effects were observed when the small-molecule (sm)CDKI was administered orally or i.p. (7). A separate series of our experiments disclosed that cell-cycle progression is not the only function of CDK (8).…”